Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clazakizumab - CSL Behring

Next Previous
Drug Profile

Clazakizumab - CSL Behring

Alternative Names: ALD-518; Anti-IL-6 mAb - CSL Behring; BMS-945429; CSL 300

Latest Information Update: 09 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer CSL Behring; ICON; Lundbeck Seattle BioPharmaceuticals Inc.; Vitaeris
  • Class Anti-inflammatories; Antianaemics; Antipsoriatics; Antirheumatics; Antivirals; Monoclonal antibodies; Urologics
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal transplant rejection
  • Phase II/III Renal failure
  • Phase II COVID 2019 infections; Inflammation
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 08 Apr 2024 CSL Behring terminates a phase III IMAGINE trial in Renal transplant rejection in Austria, Czech Republic, New Zealand, Belgium, South Korea, Taiwan, Australia, Canada, France, Germany, Netherlands, Sweden, Hungary, Spain, USA (SC) due to lack of efficacy/futility at interim analysis (NCT03744910) (EudraCT 2018-003682-34)
  • 18 Jul 2023 Phase-II clinical trials in Inflammation (In the elderly) in USA (SC) (NCT05727384)
  • 29 Nov 2022 Phase-II development in COVID-2019 infections is ongoing in USA (IV) (NCT04343989)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top